• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Am J Public Health . Seroprevalence of SARS-CoV-2 Antibodies in Rhode Island From a Statewide Random Sample

tetano

Editor, Senior Moderator
Am J Public Health


. 2021 Feb 18;e1-e4.
doi: 10.2105/AJPH.2020.306115. Online ahead of print.
Seroprevalence of SARS-CoV-2 Antibodies in Rhode Island From a Statewide Random Sample


Philip A Chan[SUP] 1 [/SUP], Ewa King[SUP] 1 [/SUP], Yizhen Xu[SUP] 1 [/SUP], William Goedel[SUP] 1 [/SUP], Leanne Lasher[SUP] 1 [/SUP], Matt Vargas[SUP] 1 [/SUP], Ken Brindamour[SUP] 1 [/SUP], Richard Huard[SUP] 1 [/SUP], Ailis Clyne[SUP] 1 [/SUP], James McDonald[SUP] 1 [/SUP], Utpala Bandy[SUP] 1 [/SUP], David Yokum[SUP] 1 [/SUP], Michelle L Rogers[SUP] 1 [/SUP], Laura Chambers[SUP] 1 [/SUP], Siena C Napoleon[SUP] 1 [/SUP], Nicole Alexander-Scott[SUP] 1 [/SUP], Joseph W Hogan[SUP] 1 [/SUP]



Affiliations

Abstract

Objectives. To characterize statewide seroprevalence and point prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Rhode Island.Methods. We conducted a cross-sectional survey of randomly selected households across Rhode Island in May 2020. Antibody-based and polymerase chain reaction (PCR)-based tests for SARS-CoV-2 were offered. Hispanics/Latinos and African Americans/Blacks were oversampled to ensure adequate representation. Seroprevalence estimations accounted for test sensitivity and specificity and were compared according to age, race/ethnicity, gender, housing environment, and transportation mode.Results. Overall, 1043 individuals from 554 households were tested (1032 antibody tests, 988 PCR tests). The estimated seroprevalence of SARS-CoV-2 antibodies was 2.1% (95% credible interval [CI] = 0.6, 4.1). Seroprevalence was 7.5% (95% CI = 1.3, 17.5) among Hispanics/Latinos, 3.8% (95% CI = 0.0, 15.0) among African Americans/Blacks, and 0.8% (95% CI = 0.0, 2.4) among non-Hispanic Whites. Overall PCR-based prevalence was 1.5% (95% CI = 0.5, 3.1).Conclusions. Rhode Island had low seroprevalence relative to other settings, but seroprevalence was substantially higher among African Americans/Blacks and Hispanics/Latinos. Rhode Island sits along the highly populated northeast corridor, making our findings broadly relevant to this region of the country. Continued monitoring via population-based sampling is needed to quantify these impacts going forward. (Am J Public Health. Published online ahead of print February 18, 2021: e1-e4. https://doi.org/10.2105/AJPH.2020.306115).
 
Back
Top Bottom